pink1 → blue1
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
WARNINGREDOSING CAN TRIGGER PSYCHOSIS
PCP-like dissociatives can cause mania, paranoia, or psychosis that outlasts the high. High doses, redosing, and sleep loss raise the risk.
O-PCE
2'-Oxo-PCE
Eticyclidone, N-ethyldeschloroketamine, deschloro-N-ethyl-ketamine, 2-Oxo-PCE
O-PCE is a lesser-known novel dissociative of the arylcyclohexylamine classcitation needed that produces dissociative, anesthetic, stimulating, and hallucinogenic effects, speculated to act primarily as an NMDA receptor antagonist. Structurally related to other arylcyclohexylamines like MXE and deschloroketamine, it emerged as a contemporary designer drug marketed through online research chemical vendors as a replacement for MXE and other dissociatives. It is reportedly habit-forming, and its pharmacological profile remains poorly characterized.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold~1 mg
Light1-5 mg
Moderate5-10 mg
Strong10-20 mg
Heavy20+ mg
Avoid frequent redosing; overdose is reported to be relatively easy due to the compound's potency and stimulating nature.
Duration
Onset20-40 minutes
After Effects2-48 hours
Total3-6 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
O-PCE produces a dissociative experience that is notably more stimulating and manic in character than ketamine or deschloroketamine, with a relatively fast onset for an arylcyclohexylamine. Lower doses yield a clear-headed, euphoric dissociation, while higher doses progress into profound detachment from the body and environment, culminating in hole states with immersive internal hallucinations. Its high potency and euphoric, energetic character give it a reputation for encouraging compulsive redosing, and heavy or repeated use is associated with confusion and delusional thinking.
Physical
The body load is light and stimulating rather than sedating, with physical euphoria, pain relief, and a floating bodily lightness giving way to motor control loss and spatial disorientation at higher doses.
Comfortable
Disconnective
Cognitive
The headspace is unusually lucid and energetic for a dissociative at low doses, with mood lift and disinhibition, but memory suppression, time distortion, and delusional or confused thinking emerge as doses climb, up to full ego dissolution during hole states.
Visual
Visual effects are primarily suppressive and disconnective rather than psychedelic, deepening with dose from mild blurring into full detachment from external vision.
Distortions
Auditory
Sounds become muffled and distant as dissociation deepens.
Tactile
Touch and pain perception are progressively dulled, consistent with the compound's anesthetic character.
See also: Dissociative Intensity Scale, Subjective Effects of Dissociatives
Pharmacology
Pharmacodynamics
No formal pharmacological studies of O-PCE have been published.citation needed Based on structure-activity relationship analysis and its structural similarity to other arylcyclohexylamine dissociatives such as ketamine and methoxetamine, O-PCE is thought to produce its effects principally through NMDA receptor antagonism. Other neurotransmitter systems may also be involved, though this remains uncharacterized.
Pharmacokinetics
There have been no studies on the pharmacokinetic profile of O-PCE and the metabolism of O-PCE is unknown.
Metabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
Repeated O-PCE use over time can produce tolerance to many effects, so users may need larger amounts to obtain comparable results.
Baseline Reset
1-2 weeks
Half Tolerance
3-7 days
Cross Tolerance
Dissociatives
Harm Potential
Addiction & Dependence
Psychological
ModerateO-PCE is regarded as moderately addictive and as having high abuse potential, and it can cause psychological dependence in some users. Compulsive redosing is commonly reported, particularly due to its potency and stimulating nature.
Physical
LowCravings and withdrawal effects may occur when a person suddenly stops usage after addiction has developed, though the severity of physical dependence appears less pronounced than the psychological component.
Toxicity
Urinary System
Repeated and excessive use over extended periods may cause bladder and urinary tract problems similar to those seen with ketamine, including urinary frequency, urgency, pressure, pelvic and bladder pain, hematuria, and incontinence; occasional use appears to carry minimal risk.
Psychosis Risk
Mania is listed among potential cognitive effects at higher doses. As with other dissociatives, O-PCE may carry some risk of adverse psychological reactions including delusions and psychosis, particularly at higher doses or in predisposed individuals.
History & Culture
O-PCE emerged as part of the wave of novel arylcyclohexylamine designer drugs that appeared on the online research chemical market following the decline in MXE availability.citation needed The compound was specifically developed and marketed as a functional replacement for MXE and other…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
International
O-PCE is not listed under the 1961 Single Convention on Narcotic Drugs. It is not listed under the 1971 Convention on Psychotropic Substances. It is not listed under the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
By Country
Illegal7
Czech RepublicSchedule I (List 4)Classified as a controlled substance under Schedule I (List 4).1 Despite this scheduling, limited exceptions exist for research purposes and restricted therapeutic applications.citation needed
JapanIllegal医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第二条第十五項に規定する指定薬物及び同法第七十六条の四に規定する医療等の用途を定める省令の一部を改正する省令（平成30年厚生労働省令第109号）67
O-PCE is a designated drug under the Pharmaceuticals and Medical Devices Act framework. The 2018 ministerial amendment lists 2-(ethylamino)-2-phenylcyclohexanone and its salts, including O-PCE, as a designated drug; from 1 September 2018, manufacture, importation, sale, possession, use, and related handling of the substance or products containing it are prohibited in principle.
PolandIllegalRegulation of the Minister of Health of 17 August 2018 on the list of psychotropic substances, narcotic drugs and new psychoactive substances151617
O-PCE is listed by name as 2-Oxo-PCE (2-(etyloamino)-2-fenylocykloheksan-1-on) in Poland's list of new psychoactive substances and is also within the arylcyclohexylamine-derivative group VII-NPS. Unlawful possession of a new psychoactive substance is punishable by a fine; unlawful commercial distribution is punishable by a fine and imprisonment from six months to eight years under the Act on Counteracting Drug Addiction.
SingaporeIllegalO-PCE is listed as 2-(Ethylamino)-2-phenyl-cyclohexan-1-one, also known as Deschloro-N-ethyl-ketamine, in the First Schedule to Singapore's Misuse of Drugs Act 1973. It has been a Class A controlled drug since 1 May 2021. Trafficking, manufacture, import, export, possession and consumption of the substance are offences under the Act.
SwedenIllegalO-PCE is classified as a narcotic in Annex 1 to Sweden's Ordinance (1992:1554) on control of narcotics, as amended by SFS 2023:5. The amendment entered into force on 14 February 2023. Unauthorized possession, use, transfer, and manufacture for misuse are narcotics offences under the Narcotic Drugs (Penal Law) Act (1968:64).
United KingdomIllegalMisuse of Drugs Act 1971, Schedule 2, Part II24
Controlled under the Misuse of Drugs Act 1971. As an N-alkyl derivative of 2-amino-2-phenylcyclohexanone, it falls under the arylcyclohexylamine generic clause introduced by Statutory Instrument 2013/239,25 which became effective on February 26, 2013. Possession, production, supply, and importation are prohibited.
Controlled / restricted1
GermanyRestrictedRegulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019.24 Manufacturing and importing for market distribution, administering to others, and commercial trading are criminally punishable offenses.5 Personal possession remains illegal but is not subject to criminal penalties.35
Not scheduled1
NetherlandsNot scheduledDutch Opium Act (Opiumwet), current consolidated BWB state BWBR0001941 effective 9 July 2026 onward; Articles 2, 2a, 3a, 3aa, 10, 10b and 10c and Lists I, II and IA; latest List IA amendment Staatsblad 2026, 179.891011121314
O-PCE is not currently scheduled under Dutch drug legislation in the current consolidated Lists I, II and IA, including the latest List IA amendment. Commercial availability does not itself determine legality. The Opiumwet schedules concern the identified O-PCE structure only. O-PCE does not fall within the four current List IA group headings for 2-fenethylamine derivatives, synthetic cannabinoids, 4-aminopiperidine derivatives, or benzimidazole opioids and nitazenes. The separate 2-fluordeschloorketamine entry is not a basis for applying an analogue rule to O-PCE.
References
Source Pages
Citations
- Nařízení vlády č. 463/2013 Sb., o seznamech návykových látek — Příloha č. 4 (Seznam č. 4 psychotropních látek). Česká republika (2013). https://krajta.slv.cz/2013/463/par_1-pism_d-bod_21
- Anlage 1 NpSG — Neue-psychoaktive-Stoffe-Gesetz Anlage (Nummer 6: Von Arylcyclohexyl(methyl)amin abgeleitete Verbindungen). Bundesministerium der Justiz und für Verbraucherschutz (2019). https://www.gesetze-im-internet.de/npsg/anlage_1.html12
- § 3 NpSG — Unerlaubter Umgang mit neuen psychoaktiven Stoffen. Bundesministerium der Justiz und für Verbraucherschutz (2017). https://www.gesetze-im-internet.de/npsg/__3.html12
- Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes. (2019). http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl119s1083.pdf1
- § 4 NpSG. (2019). https://www.gesetze-im-internet.de/npsg/__4.html12
- 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第二条第十五項に規定する指定薬物及び同法第七十六条の四に規定する医療等の用途を定める省令の一部を改正する省令（平成30年厚生労働省令第109号）. mhlw.go.jp (n.d.). https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/oshirase/20180822-2.html1
- 医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律第二条第十五項に規定する指定薬物及び同法第七十六条の四に規定する医療等の用途を定める省令の一部を改正する省令（平成30年厚生労働省令第109号）. mhlw.go.jp (n.d.). https://www.mhlw.go.jp/content/11120000/001714395.pdf1
- Official source. wetten.overheid.nl (n.d.). https://wetten.overheid.nl/BWBR0001941/2026-07-09/0/informatie1
- Official source. repository.officiele-overheidspublicaties.nl (n.d.). https://repository.officiele-overheidspublicaties.nl/bwb/BWBR0001941/2026-07-09_0/xml/BWBR0001941_2026-07-09_0.xml1
- Official source. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/cid/132989542/property/IUPACName,MolecularFormula,CanonicalSMILES/JSON1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes7 human edits · latest
Times are UTCNewest first
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the O-PCE article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
